March 31, 2021
CheckMate 577 is the first trial to demonstrate the effectiveness of immunotherapy in the adjuvant setting for esophageal cancer or TEG
Although trimodal therapy (neoadjuvant chemoradiation therapy followed by surgery) is the current standard, the risk of relapse is high, especially for 70% to 75% of patients who do not
Do you like it?
No translations available for this page
Send to Email Address
Your Email Address